Sponsored by World Molecular Imaging Society and the Beth Israel Deaconess Medical Center of Harvard Medical School
BOSTON, Oct. 21, 2013 /PRNewswire-USNewswire/ -- Molecular imaging holds the promise for improved patient management in medicine and surgery. To realize this goal, a thorough understanding of the instrumentation and diagnostic agents that comprise the field is necessary. Emerging methodologies in molecular imaging that could become part of clinical practice within the next decade will be highlighted at the Advanced Molecular Imaging and Its Clinical Translation course, here at the Fairmont Copley Plaza, October 27-30, 2013.
Sponsored by the World Molecular Imaging Society (WMIS) and the Department of Medicine at Beth Israel Deaconess Medical Center (BIDMC) / Harvard Medical School, the Advanced Molecular Imaging and its Clinical Translation Course brings together some of the most influential thought leaders and provides a comprehensive educational experience in the physics, chemistry, engineering, and physiology that are the foundation of molecular imaging. Key leaders from industry will bring their perspective on how intellectual property, regulatory approval, and reimbursement impact patient care. Faculty from around the world specializing in basic science, clinical translation, and clinical applications have been carefully chosen to bring course attendees to the state-of-the-art in the field.
"Imaging and biomarker application is at the core of the pursuit of translational medicine. Clinical translation is a focus for WMIS in 2014 and partnering with Harvard Medical School allows us to extend our educational offerings and create a greater awareness of molecular imaging and its use in defining precision medicine," said Anna M. Wu, Ph.D., President of WMIS, Professor and Vice Chair of Molecular and Medical Pharmacology and Associate Director of Crump Institute for Molecular Imaging at the David Geffen School of Medicine, UCLA.Most aspects of molecular imaging will be covered, including optical imaging, SPECT, PET, CT, MRI, ultrasound, combinations thereof, contrast agent chemistry, radiotracer development, preclinical imaging, regulatory, statistical, reimbursement, and logistical issues surrounding clinical translation, and state-of-the-art clinical imaging in cancer, heart disease, neurology, and other human conditions.